In Brief: CM Systems 2 Gel
This article was originally published in The Tan Sheet
Executive Summary
CM Systems 2 Gel: Topical pain relieving gel is an unapproved new drug, FDA informs Miami Beach, Fla.-based Colloidal Products in a recent warning letter. The gel is mislabeled as being for "treatment of diabetic neuropathy, shingles, herniated discs, headaches, retention of liquids and `phantom pain,'" the letter notes. In addition, the product fails to identify its active ingredients and does not bear adequate directions for use, FDA says...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning